FLOW CYTOMETRY IN THE DIAGNOSIS AND MONITORING OF MINIMAL RESIDUAL DISEASE IN MULTIPLE MYELOMA

Cover Page

Cite item

Full Text

Abstract

Over the past 20 years, approaches to the therapy of multiple myeloma have undergone significant changes, and frequency of achieving remission of the disease increased. The new diagnostic methods allowed evaluating the more deep therapy response and predicting the relapse: allele-specific polymerase chain reaction, next generation sequencing, multicolor flow cytometry may detect a minimal residual disease (MRD) with a sensitivity of 10–5 to 10–6. Evaluation of MRD by flow cytometry is a dynamically developing direction of research. The aim of multicenter investigations using flow cytometry for MRD-searching in multiple myeloma is standardization, increasing the sensitivity and specificity of this method. The article presents data on the methods used in monitoring MRD, as well as advances in flow cytometry. 

About the authors

I. V. Galtseva

Hematological Research Center, Ministry of Health of Russia

Author for correspondence.
Email: irinagaltseva@gmail.com
4a Noviy Zykovskiy Proezd, Moscow 125167 Russian Federation

Y. O. Davydova

Hematological Research Center, Ministry of Health of Russia

4a Noviy Zykovskiy Proezd, Moscow 125167 Russian Federation

N. M. Kapranov

Hematological Research Center, Ministry of Health of Russia

4a Noviy Zykovskiy Proezd, Moscow 125167 Russian Federation

U. L. Julakyan

Hematological Research Center, Ministry of Health of Russia

4a Noviy Zykovskiy Proezd, Moscow 125167 Russian Federation

L. P. Mendeleeva

Hematological Research Center, Ministry of Health of Russia

4a Noviy Zykovskiy Proezd, Moscow 125167 Russian Federation

References

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c)



СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-36928 от  21.07.2009.